

COLLABORATIVE PROJECTS SANCTIONED DURING 2008-09

Sl. No.	File No.	Title	PI Name & Institution / Industry Address	Duration	Total Cost (Rs.in lakhs)	DST share (Rs. in lakhs)
1.	VI-D&P/245/08-09/TDT	Development of biodegradable sustained release formulations for human growth hormone (hGH)	Dr. N. Udupa, Professor & PI, Manipal College of Pharmaceutical Sciences, Manipal University, Manipal-576104. Dr. K.G. Rajendran, Head – Knowledge Cell, USV Limited, B.S.D. Marg, Govandi (East), Mumbai-400088	3 years	144.45	46.017
2.	VI-D&P/247/08-09/TDT	Development of Mechanism based Antidiabetic Formulation, Standardization from Indian Traditional Herbs viz., Bioavailability, Stability studies	Dr. T. Subburaju, Dean – Research (Dept. of Life Sciences), Karpagam Arts and Science College, Pollachi Main Road, Eachanari Post, Coimbatore-641021 Mr. Jai Muruges, Manager (Quality Control & Quality Assurance), KNISS Laboratories Pvt. Ltd., Plot No.9, Multi Industrial Estate, Gerugambakkam, Chennai-602101	3 years	125.62	85.216
3.	VI-D&P/246/08-09/TDT	Development of a bispecific single chain antibody neutralizing edema toxin and lethal toxin of anthrax	Dr. Rakesh Bhatnagar, Professor, School of Biotechnology, JNU, New Delhi-110067 Dr. Atul Thatai, Vice President, ARBRO Pharmaceuticals Ltd., 6/14, Kirti Nagar Industrial Area, New Delhi-110015	3 years	177.454	142.564
4.	VI-D&P/271/08-09/TDT	Standardization, validation and development of herbal formulation for the treatment of neuropathic pain	Dr. M. Ramanathan, Professor of Pharmacology, PSG College of Pharmacy, Post Box No.1674, Peelamedu, Coimbatore-641004 Dr. Ramesh R. Varier, Managing Director, M/s Arya Vaidya Nilayam, 175-A, Vilachery Main Road, Madurai-625004	3 years	51.56	39.79

:2:

5.	VI-D&P/253/08-09/TDT	Development, standardization and safety of a poly-herbal formulation in the management of obesity associated hyperlipidemia	Dr. J. Venkatesh, Veterinary Officer & PI, Sri Ramachandra University, Ramachandra Nagar, Porur, Chennai-600116 M/s Arvind Remedies Ltd., 38-40, SIDCO Industrial Estate, Kakkalur-602003.	3 years	95.102	58.91
6.	VI-D&P/268/08-09/TDT	Development of novel antifungal agents including hybrid molecules	Dr. H.B. Borate, Scientist – Division of Organic Chemistry, National Chemical Laboratory, Dr. Homi Bhabha Road, Pune-411008 Sh. M.A. Chandavarkar, Chairman, FDC Ltd., 142-148, S.V. Road, Jogeshwari (West), Mumbai-400102	3 years	178.35	44.445

FACILITY PROJECTS SANCTIONED DURING 2008-09

Sl. No.	File No.	Title	PI Name & Institution / Industry Address	Duration	Total Cost (Rs.in lakhs)	DST share (Rs. in lakhs)
1.	VI-D&P/258/08-09/TDT	Development for toxicity screening of nanoparticles used for Drug Delivery and to elucidate its mechanism of action	Dr. Kulbushan Tikoo, Associate Professor, Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research, Sector-67, Mohali-160062	3 years	250.00	250.00
2.	VI-D&P/242/07-08/TDT	National facility to identify potential drugs targets through functional cell dynamics	Dr. S. Mahalingam, Associate Professor, Department of Biotechnology, Indian Institute of Technology, Madras, Chennai-600036	2 years	574.42	474.42
3.	VI-D&P/267/08-09/TDT	National facility for the development of Herbo-metallic preparations of Ayurveda, Siddha and Unani	Prof. Victor Rajamanickam, Dean – CARISM, SASTRA University, Thirumalaisamudram, Thanjavur-613402	3 years	1122.09	785.46

LOAN PROJECTS SANCTIONED DURING 2008-09

Sl. No.	File No.	Title	PI Name & Institution / Industry Address	Duration	Total Cost (Rs.in lakhs)	DST share (Rs. in lakhs)
1.	VI-D&P/233/07-08/TDT	Synthesis of natural and modified nucleosides and phosphoramidites for the development and manufacturing of analogs (DNA& RNA) for oligonucleotides based therapeutic medicines and diagnostic kits	Dr. Balakrishna K. Kulkarni, Director (R&D and Business Development and Chief Technology Officer), Innovassynth Technologies (I) Ltd., Paragon Condominium, 3rd Floor, Opp. Century Mills, P. Budhkar Marg, Lower Parel, Mumbai-400013	2 years	2230.00	1100.00
2.	VI-D&P/262/08-09/TDT	Development of ABI 873, a Synthetic Ribozyme as Anti-cancer Agents	Dr. Ramani Aiyer, Chief Scientific Officer, Actis Biologics Pvt. Ltd., 201, Vedant, 2 nd Floor, 779, Makwana Road, Off Andheri Kurla Road, Marol Andheri East, Mumbai-400059	3 years	3499.10	1747.00
3.	VI-D&P/281/08-09/TDT	Clot specific streptokinase (SMRX11), A novel thrombolytic for the treatment of Cardiovascular Disease for pre-clinical animal toxicology	Dr. Yatindra Prashar, CEO, Symmetrix Biotech Pvt. Ltd., Institute of Microbial Technology, Sector-39A, Chandigarh-160036	1 year	1400.00	700.00
4.	VI-D&P/279/08-09/TDT	Chiral technology for the synthesis of camptothecin analogs and development of novel delivery systems for SN-38, the active metabolite of irinotecan	Dr. A.V., Rama Rao, Chairman & Managing Director, Avra Laboratories Pvt. Ltd., Plot No.9/15 (2&3), Road No.6, IDA Nacharam, Hyderabad-501507	2 years	1180.00	590.00
5.	VI-D&P/280/08-09/TDT	Establishing a state-of-the-art animal facilities for contract research, testing of indigenously developed biological devices and breeding of SPF animal for clinical research and commercial use	Dr. Soma Guhathakurta, Joint Managing Director, Frontier Tissueline Pvt. Ltd., R-30-C, Ambattur Industrial Estate Road, Mugappair, Chennai-600101	3 years	2519.06	800.00
6.	VII-PRDSF/12(L)/04-05/TDT	Development of atherocid as a drug and pharmaceutical for Coronary Heart Disease (CHD) and CHD risk equivalents	Mr. Vachaspati Tripathi, Proprietor, Surya Pharmaceuticals, 71, Krishna Bagh, Nagwa, Varanasi-221005	3 years	142.84	65.00

GRANTS-IN-AID PROJECTS SANCTIONED TO INDUSTRY DURING 2008-09

Sl. No.	File No.	Title	PI Name & Institution / Industry Address	Duration	Total Cost (Rs.in lakhs)	DST share (Rs. in lakhs)
1.	VI-D&P/282/08-09/TDT	A prospective, multi-centric, randomized, two-arm, Phase III study to assess safety and efficacy of infusion of Amphomul® (Amphotericin B Emulsion) as compared to Ambisome® in patients of Visceral Leishmaniasis (Kala Azar)	Mrs. Kavita Khanna, Advisor – Public Health, Bharat Serums and Vaccines Ltd., 17 th Floor, Hoechst House, Nariman Point, Mumbai - 400021	18 months	827.82	650.00
2.	VI-D&P/259/08-09/TDT	RBx11160 (arterolane) maleate & piperazine phosphate – A novel antimalarial fixed dose combination product for India and developing countries	Dr. Sudershan Arora, President – R&D, M/s Ranbaxy Laboratories Limited, Plot No.77B, IFFCO Road, Sector-18, Udyog Vihar Industrial Area, Gurgaon-122015	1 year	2634.00	1000.00